EPARs - Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)

EPARs for authorised medicinal products for human use - Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals

FICHA FARMACOLÓGICA de Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted). Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. Febrero 2009.

Active Substance
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/Vietnam/1194/2004 NIBRG-14

International Nonproprietary Name or Common Name
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/Vietnam/1194/2004 NIBRG-14
Pharmaco-therapeutic Group
Influenza vaccines
ATC Code
J07BB02
Therapeutic Indication
Active immunisation against H5N1 subtype of Influenza A virus.

This indication is based on immunogenicity data from healthy subjects aged 18-60 years following administration of two doses of vaccine prepared from A/VietNam/1194/2004 NIBRG-14 (H5N1) (see section 5.1).

Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals should be used in accordance with official guidance.